{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:55:25Z","timestamp":1793818525689,"version":"4.6.1"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:sec id=\"ab-ooi230043-4\"><jats:title>Importance<\/jats:title><jats:p>There is growing interest in the use of circulating plasma tumor human papillomavirus (HPV) DNA for diagnosis and surveillance of patients with HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). Recent advances in the assays, combining the identification of circulating HPV tumor DNA and tumor DNA fragment analysis (tumor tissue\u2013modified viral [TTMV]-HPV DNA), have been shown to be highly accurate. However, use of these newer techniques has been limited to small cohort studies and clinical trials.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230043-5\"><jats:title>Objective<\/jats:title><jats:p>To establish the clinical efficacy of plasma TTMV-HPV DNA testing in the diagnosis and surveillance of HPV-associated OPSCC in a contemporary clinical setting.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230043-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective observational cohort study included patients with OPSCC who underwent TTMV-HPV DNA testing between April 2020 and September 2022 during the course of routine clinical care. For the diagnosis cohort, patients with at least 1 TTMV-HPV DNA measurement prior to initiation of primary therapy were included. Patients were included in the surveillance cohort if they had at least 1 TTMV-HPV DNA test performed after completion of definitive or salvage therapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230043-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Per-test performance metrics, including sensitivity, specificity, positive predictive value, and negative predictive value, for TTMV-HPV DNA testing.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230043-8\"><jats:title>Results<\/jats:title><jats:p>Of 399 patients included in the analysis, 163 were in the diagnostic cohort (median [IQR] age, 63 [56-68.5] years; 142 [87.1%] male), and 290 were in the surveillance cohort (median [IQR] age, 63 [57-70] years; 237 [81.7%] male). Of the 163 patients in the diagnostic cohort, 152 (93.3%) had HPV-associated OPSCC while 11 (6.7%) had HPV-negative OPSCC. The TTMV-HPV DNA sensitivity in pretreatment diagnosis was 91.5% (95% CI, 85.8%-95.4% [139 of 152 tests]), and the specificity was 100% (95% CI, 71.5%-100% [11 of 11 tests]). In the surveillance cohort, 591 tests conducted in 290 patients were evaluated. A total of 23 patients had molecularly confirmed pathologic recurrences. The TTMV-HPV DNA test demonstrated sensitivity of 88.4% (95% CI, 74.9%-96.1% [38 of 43 tests]) and specificity of 100% (95% CI, 99.3%-100% [548 of 548 tests]) in detecting the recurrences. Positive predictive value was 100% (95% CI, 90.7%-100% [38 of 38 tests]), and negative predictive value was 99.1% (95% CI, 97.9%-99.7% [548 of 553 tests]). The median (range) lead time from positive TTMV-HPV DNA test to pathologic confirmation was 47 (0-507) days.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230043-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This cohort study demonstrated that when evaluated in a clinical setting, the TTMV-HPV DNA assay demonstrated 100% specificity in both diagnosis and surveillance. However, the sensitivity was 91.5% for the diagnosis cohort and 88.4% for the surveillance cohort, signifying that nearly 1 in 10 negative tests among patients with HPV-associated OPSCC was a false negative. Additional research is required to validate the assay\u2019s performance and, if validated, then further research into the implementation of this assay into standard clinical practice guidelines will be required.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoto.2023.1937","type":"journal-article","created":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T20:30:31Z","timestamp":1688934631000},"page":"971","source":"Crossref","is-referenced-by-count":99,"title":["Performance of Liquid Biopsy for Diagnosis and Surveillance of Human Papillomavirus\u2013Associated Oropharyngeal Cancer"],"prefix":"10.1001","volume":"149","author":[{"given":"Rocco M.","family":"Ferrandino","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sida","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharine","family":"Kappauf","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Barlow","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon S.","family":"Gold","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Westra","sequence":"additional","affiliation":[{"name":"Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita S.","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohemmed N.","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall R.","family":"Posner","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof J.","family":"Misiukiewicz","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Bakst","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal K.","family":"Sindhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Genden","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Roof","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"ooi230043r1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","article-title":"HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management.","volume":"19","author":"Lechner","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"32","key":"ooi230043r2","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States.","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J Clin Oncol"},{"key":"ooi230043r3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.966899","article-title":"Current perspectives on recurrent HPV-mediated oropharyngeal cancer.","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"ooi230043r4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jnci\/djn011","article-title":"Improved survival of patients with human papillomavirus\u2013positive head and neck squamous cell carcinoma in a prospective clinical trial.","volume":"100","author":"Fakhry","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"ooi230043r5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer.","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"ooi230043r6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1067321","article-title":"What is the future of treatment de-escalation for HPV-positive oropharyngeal cancer? a review of ongoing clinical trials.","volume":"12","author":"Mensour","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"ooi230043r7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1634\/theoncologist.2020-0303","article-title":"Optimizing treatment de-escalation in head and neck cancer: current and future perspectives.","volume":"26","author":"Rosenberg","year":"2021","journal-title":"Oncologist"},{"issue":"5","key":"ooi230043r8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/cyt.2018.29.issue-5","article-title":"Cytology and direct human papillomavirus testing on fine needle aspirates from cervical lymph node metastases of patients with oropharyngeal squamous cell carcinoma or occult primary.","volume":"29","author":"Rollo","year":"2018","journal-title":"Cytopathology"},{"key":"ooi230043r9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.humpath.2016.04.002","article-title":"The utility of p16 immunostaining in fine needle aspiration in p16-positive head and neck squamous cell carcinoma.","volume":"54","author":"Xu","year":"2016","journal-title":"Hum Pathol"},{"key":"ooi230043r10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.oraloncology.2019.02.006","article-title":"Real-time PCR HPV genotyping in fine needle aspirations of metastatic head and neck squamous cell carcinoma: exposing the limitations of conventional p16 immunostaining.","volume":"90","author":"El-Salem","year":"2019","journal-title":"Oral Oncol"},{"key":"ooi230043r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.105776","article-title":"The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma.","volume":"126","author":"Haring","year":"2022","journal-title":"Oral Oncol"},{"issue":"10","key":"ooi230043r12","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer.","volume":"38","author":"Chera","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15","key":"ooi230043r13","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","article-title":"Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer.","volume":"25","author":"Chera","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"ooi230043r14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3390\/diagnostics13040725","article-title":"Analytical validation of NavDx, a cfDNA-based fragmentomic profiling assay for HPV-driven cancers.","volume":"13","author":"Gunning","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"ooi230043r15","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/ijc.v151.7","article-title":"Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positive head and neck cancer.","volume":"151","author":"Rettig","year":"2022","journal-title":"Int J Cancer"},{"issue":"7","key":"ooi230043r16","doi-asserted-by":"publisher","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","article-title":"Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.","volume":"18","author":"Pfister","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"ooi230043r17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12967-020-02330-y","article-title":"Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer.","volume":"18","author":"Rutkowski","year":"2020","journal-title":"J Transl Med"},{"issue":"14","key":"ooi230043r18","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1200\/JCO.22.00264","article-title":"Clinical uncertainties of circulating tumor DNA in human papillomavirus\u2013related oropharyngeal squamous cell carcinoma in the absence of National Comprehensive Cancer Network Guidelines.","volume":"41","author":"Xie","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"ooi230043r19","doi-asserted-by":"publisher","first-page":"5946","DOI":"10.3390\/cancers14235946","article-title":"Circulating human papillomavirus DNA in head and neck squamous cell carcinoma: possible applications and future directions.","volume":"14","author":"Adilbay","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"ooi230043r20","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/lary.v132.3","article-title":"Cell-free human papillomavirus-DNA for monitoring treatment response of head and neck squamous cell carcinoma: systematic review and meta-analysis.","volume":"132","author":"Campo","year":"2022","journal-title":"Laryngoscope"},{"issue":"4","key":"ooi230043r21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1158\/1078-0432.CCR-21-3151","article-title":"Cell-free HPV DNA provides an accurate and rapid diagnosis of HPV-associated head and neck cancer.","volume":"28","author":"Siravegna","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"ooi230043r22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(23)00013-X","article-title":"Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis.","volume":"24","author":"Mehanna","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1-2","key":"ooi230043r23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000496158","article-title":"Current status of p16 immunohistochemistry and HPV testing in fine needle aspiration specimens of the head and neck.","volume":"64","author":"Jalaly","year":"2020","journal-title":"Acta Cytol"},{"issue":"1","key":"ooi230043r24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/cncy.v130.1","article-title":"Liquid biopsy for the diagnosis of HPV-associated head and neck cancer.","volume":"130","author":"Faden","year":"2022","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"ooi230043r25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/lary.v123.1","article-title":"A new paradigm for the diagnosis and management of unknown primary tumors of the head and neck: a role for transoral robotic surgery.","volume":"123","author":"Mehta","year":"2013","journal-title":"Laryngoscope"},{"issue":"22","key":"ooi230043r26","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1200\/JCO.20.00275","article-title":"Diagnosis and management of squamous cell carcinoma of unknown primary in the head and neck: ASCO guideline.","volume":"38","author":"Maghami","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"ooi230043r27","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.3390\/cancers12102997","article-title":"Cell-free HPV-DNA as a biomarker for oropharyngeal squamous cell carcinoma\u2014a step towards personalized medicine?","volume":"12","author":"Wuerdemann","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"19","key":"ooi230043r28","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1002\/cncr.v119.19","article-title":"Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma.","volume":"119","author":"Lin","year":"2013","journal-title":"Cancer"},{"key":"ooi230043r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106357","article-title":"The use of plasma circulating tumor DNA for early detection of oligometastatic disease in HPV positive oropharyngeal squamous cell carcinoma.","volume":"139","author":"Zhang","year":"2023","journal-title":"Oral Oncol"},{"issue":"1","key":"ooi230043r30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2967\/jnumed.108.055806","article-title":"Does 18F-FDG PET\/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up?","volume":"50","author":"Abgral","year":"2009","journal-title":"J Nucl Med"},{"issue":"2","key":"ooi230043r31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00405-019-05684-2","article-title":"FDG-PET\/CT in the surveillance of head and neck cancer following radiotherapy.","volume":"277","author":"Ris\u00f8r","year":"2020","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"6","key":"ooi230043r32","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/bjc.2017.258","article-title":"Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma.","volume":"117","author":"Lee","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"ooi230043r33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4274\/Mirt","article-title":"Limits of tumor detectability in nuclear medicine and PET.","volume":"21","author":"Erdi","year":"2012","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"2-3","key":"ooi230043r35","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S0959-8049(05)80068-1","article-title":"The value of follow-up in patients treated for squamous cell carcinoma of the head and neck.","volume":"28","author":"Boysen","year":"1992","journal-title":"Eur J Cancer"},{"issue":"8","key":"ooi230043r36","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00405-010-1461-2","article-title":"The follow-up of patients with head and neck cancer: an analysis of 1,039 patients.","volume":"268","author":"Kothari","year":"2011","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"19","key":"ooi230043r37","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1158\/1078-0432.CCR-22-0562","article-title":"Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma.","volume":"28","author":"Berger","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ooi230043r34","volume-title":"Nuclear Medicine PET\/CT Head and Neck Cancer Assessment, Protocols, And Interpretation","author":"Eyassu","year":"2023"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2807242\/jamaotolaryngology_ferrandino_2023_oi_230043_1699458260.45479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T16:05:13Z","timestamp":1699545913000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2807242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2023.1937","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}